What do the trials say — and why is the evidence so clean?
B12's evidence base has the cleanest structure in this library: a replacement-therapy tier (correct measured deficiency, watch the blood and nerves recover) that approaches the certainty of iron itself, an oral-versus-injection literature that overturned a decades-old convention, and — at the edges — the mood and cognition associations where the trials are honestly modest. The field teaches replacement logic at its purest: the deficient have everything to gain, the replete have nothing, and the molecule is safe enough that the diagnostic discipline, not the dose, is the medicine.
The replacement-therapy field teaches population-conditional reading at its cleanest:
The fatal anemia-neuropathy syndrome enters medicine — a death sentence with a two-to-five-year course, cause unknown.
Half a pound of liver daily reverses the previously fatal disease — empirical brilliance before the molecule exists. The 1934 Nobel follows.
The gastric factor whose absence causes pernicious anemia — the absorption cascade's key step, mapped before the vitamin it transports was known.
Two competing teams (Folkers at Merck, Smith at Glaxo) purify the anti-pernicious factor from liver — the last classic vitamin discovered.
High-dose oral B12 corrects pernicious anemia via passive absorption — the injection-only convention falls to data after forty years of elegant practice.
Population fortification, the vegan pattern's structural requirement recognized by every dietetic body, and the metabolic-marker era (MMA/homocysteine) refining borderline diagnosis.
POPULATION · Patients with documented pernicious anemia, 1,000 mcg oral B12 daily vs. injection
FINDING · High-dose oral B12 corrected and maintained blood counts and B12 levels as effectively as injections — passive absorption (~1% of the high dose) sufficient despite complete intrinsic-factor failure.
LIMITATION · Era and sample sizes (by modern standards modest) — but the finding has been repeatedly confirmed and now anchors guidelines worldwide. The assumption overturned by data.
POPULATION · 33 patients with cobalamin deficiency (various causes), 2,000 mcg oral vs. 1,000 mcg IM daily
FINDING · The oral group achieved greater serum B12 increases and greater MMA reduction than the injected group — the modern confirmation trial.
LIMITATION · Small sample, mixed deficiency etiologies — but the direction was decisive, and the trial is the modern citation for the oral route's legitimacy.
POPULATION · Diabetes patients on long-term metformin across cohort studies and the DPPOS
FINDING · Long-term metformin use associates with lower B12 levels and elevated deficiency prevalence (~6–20% in long-duration users) — the drug-supplement interaction our diabetes and gut pages teach.
LIMITATION · Association with variable adjustment; the mechanism (IF-receptor interference) remains debated — but the prevalence signal is consistent enough that periodic B12 checking in long-term metformin users is guideline-recommended.
POPULATION · Long-term acid-suppression users vs. controls across pharmacoepidemiologic studies
FINDING · Chronic PPI (≥2 years) use associates with increased B12 deficiency risk — the acid-release step of the cascade, impaired by the medication.
LIMITATION · Observational with confounding by indication (PPI users differ); the biologic mechanism is direct. Our acid-reflux page teaches the depletion link as part of long-term PPI care.
POPULATION · Population-level folic-acid fortification analyses with B12-status monitoring
FINDING · Folate fortification corrected folate-deficiency anemia broadly while raising the theoretical masking risk for undiagnosed B12 deficiency in the elderly — the population-scale version of the masking rule.
LIMITATION · Ecological and modeling analyses; the predicted masking-driven neuropathy increase has not clearly materialized at population scale — the rule remains a clinical-level caution rather than a population-reversal argument.